Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1  by Makris, A. et al.
see commentary on page 959
Uteroplacental ischemia results in proteinuric
hypertension and elevated sFLT-1
A Makris1, C Thornton1,2, J Thompson4, S Thomson3, R Martin4, R Ogle2, R Waugh5, P McKenzie6,
P Kirwan7 and A Hennessy1,3
1Vascular Immunology Laboratory, Heart Research Institute and University of Sydney, NSW, Australia; 2Department of Obstetrics and
Gynaecology, Royal Prince Alfred Hospital, New South Wales, Australia; 3Department of Nephrology, Royal Prince Alfred Hospital, New
South Wales, Australia; 4Department of Surgical Oncology, Royal Prince Alfred Hospital, New South Wales, Australia; 5Department of
Radiology, Royal Prince Alfred Hospital, New South Wales, Australia; 6Department of Anatomical Pathology, Royal Prince Alfred
Hospital, New South Wales, Australia and 7Department of Anatomical Pathology, Concord Hospital, New South Wales, Australia
Preeclampsia is a complication of pregnancy with significant
morbidity and mortality for the mother and the fetus.
Presumptions are made that placental hypoxia has a
causative role in the clinical syndrome. Furthermore, soluble
fms-like tyrosine kinase 1 (sFLT-1) has been shown to have a
role in the maternal syndrome of preeclampsia. We
investigated the relationship between uteroplacental
ischemia (UPI), the maternal clinical syndrome of
preeclampsia and sFLT-1 in non-human primates. The
induction of UPI in a pregnant non-human primate resulted
in the development of a clinical entity analogous to human
preeclampsia. This was illustrated by the increase in blood
pressure, development of proteinuria, and renal histological
changes identical to human preeclampsia. A significant
elevation in the placental and peripheral blood mononuclear
cell sFLT-1 mRNA expression was noted, translating to a
significant elevation in circulating sFLT-1. Thus, this sequence
suggests that a pathogenic reduction in placental perfusion
results in the development of the maternal syndrome of
preeclampsia and an increase in circulating sFLT-1, which is
derived both from placental and extra-placental sources.
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Preeclampsia is a hypertensive disorder of pregnancy
affecting approximately 5% of pregnancies but resulting in
significant maternal and fetal morbidity and mortality.
Preeclampsia is a two-stage disorder.1 In Stage 1, pathogenic
placental changes are established resulting in the probable
reduced placental perfusion. Pathogenic changes include
inadequate invasion of the spiral arteries into the myome-
trium and incomplete trophoblast endothelialization.2 The
multisystem clinical manifestations of the syndrome of
preeclampsia define Stage 2. The clinical manifestations
results from endothelial dysfunction and systemically results
in various degrees of elevated systemic vascular resistance,
vasoconstriction, and activation of the coagulation cascade,
which clinically is evident as proteinuria and renal insuffi-
ciency, hepatic dysfunction, neurological disturbances,
including seizures, hematological disturbances, and fetal
growth restriction. The factors resulting from the placental
ischemia and linking to the systemic endothelial dysfunction
are as yet undefined, although changes in oxidation,
prostaglandins and more recently cytokines have been
implicated. However, no factor yet studied has been clearly
or temporally shown to relate to changes in placental blood
flow.
Women with preeclampsia have been shown to have
elevated circulating and placental expression of soluble
fms-like tyrosine kinase 1 (sFLT-1) mRNA.3,4 Furthermore,
the increase in circulating sFLT-1 is detectable in the
circulation 6–8 weeks before the onset of clinically apparent
disease.5 Experimentally, it has been demonstrated that the
administration of sFLT-1 to rodents,3 or similarly the
inhibition of its natural ligand vascular endothelial growth
factor with vascular endothelial growth factor antibodies6
results in a clinical entity similar to human preeclampsia. The
syndrome produced is exemplified by hypertension, protei-
nuria, and renal histological changes identical to human
preeclampsia.
In vitro studies employing hypoxic culture conditions as a
surrogate for reduced placental perfusion, have investigated
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the relationship between hypoxia and sFLT-1. Hypoxic
conditions have been shown to increase the sFLT-1 produc-
tion of placental explants,7 isolated trophoblasts8 and
peripheral blood mononuclear cells (PBMC).9 There was an
inverse dose-dependant relationship between the degree of
tissue oxygenation and the sFLT-1 production demonstrated.
The degree of tissue oxygenation investigated varied, but was
generally lower than the intervillous oxygen tension in early
pregnancy (7–10 weeks gestation, normal oxygen tension
25.672.1 mm Hg).10
Animal models that replicate the underlying pathogenic
process of impairment of placenta perfusion, have been
developed to study preeclampsia.11,12 Surgical reduction of
placental perfusion in primates and rats thus far has been
non-selective for uterine blood flow. Although the maternal
phenotype has in part been studied, neither the renal
histological changes nor the timing of the factors that
mediate the maternal changes have been investigated.
We thus investigated the relationship between reduced
placental perfusion, the clinical signs of preeclampsia and the
production of sFLT-1. Our data showed that the induction of
uteroplacental ischemia (UPI) resulted in an elevation in
blood pressure (BP), development of proteinuria, and renal
histological changes identical to human preeclampsia. UPI
also resulted in an increase in circulating sFLT-1, which may
be derived from an increase in placental and PBMC sFLT-1
mRNA expression.
RESULTS
There was an approximately 40% reduction in placental
blood flow obtained in the UPI group by ligation of a
unilateral uterine artery (Table 1). No reduction in placental
perfusion was obtained in the Sham group.
UPI resulted in a clinical entity akin to human preeclampsia
The animals that underwent UPI developed a significant
increase in BP, proteinuria, renal histological changes
consistent with human preeclampsia as well as biochemical
evidence of reduced renal and placental function.
UPI resulted in an elevation of systolic (SBP) and diastolic
(DBP) blood pressure during rest and sleep (Figure 1). The
elevation in SBP in the UPI group at rest and sleep was
16.471.7 and 13.770.9 mm Hg, respectively (both Po0.05).
The elevation in DBP in the UPI group at rest and sleep was
18.572.4 and 16.372.1 mm Hg, respectively (both Po0.05).
There was no change in the BP in the Sham group. The peak
SBP and DBP in the UPI animals was 138.771.4 mm Hg and
DBP of 95.774.1 mm Hg.
There was a significant difference in urinary protein and
albumin excretion between the UPI and Sham groups
(P¼ 0.02, Figure 2). At the end of the UPI/Sham period,
the UPI and Sham groups had an average urinary protein
excretion of 61.2715.3 mg/mmol (5417135 mg/g) and 0 mg/
mmol (0 mg/g), respectively. The definition of pathological
proteinuria in human pregnancy is considered to be 430 mg/
mmol (265 mg/g).13 There was a significant difference in the
rate of clinically significant proteinuria in the animals
undergoing UPI compared with the Sham group during the
protocol (P¼ 0.034). The UPI group developed ‘clinically’
significant proteinuria between the sixth and 10th day of
reduced placental blood flow. The mirrored increase in
albumin excretion, confirms that the majority of the protein
excreted is albumin, as is the case with human preeclampsia.14
Renal histological changes were identical to human
preeclampsia after UPI as assessed by pathologists blinded
to treatment group. Light microscopy of renal biopsies of the
animals undergoing 14 days of reduced placental blood flow
compared with baseline renal biopsies, revealed expansion in
the mesangium, endothelial cell swelling and reduction in
capillary lumina (Figure 3a and b). Electron microscopy of
glomeruli demonstrated subendothelial and paramesangial
deposition of fibrin and fibrinoid material widening of the
subendothelial space and endotheliosis with relatively pre-
served podocyte foot processes (Figure 4a–d). The Sham
group renal biopsies were unchanged 14 days after the Sham
procedure compared with baseline.
The UPI group had a statistically significant higher serum
urea compared with the Sham group (UPI: 3.170.4 mmol/l
and Sham: 2.970.3 mmol/l; P¼ 0.005), higher serum
phosphate (UPI: 0.970.04 mmol/l and Sham: 0.67
0.1 mmol/l; P¼ 0.035), and reduced serum bicarbonate
(UPI: 22.670.7 mmol/l and Sham: 24.770.6 mmol/l;
P¼ 0.048). There was no difference in serum sodium,
potassium, or creatinine. The UPI group also demonstrated
a higher serum glucose (UPI: 6.770.6 mmol/l and Sham:
4.570.4 mmol/l; P¼ 0.002) and higher serum alkaline
phosphatase (UPI: 125.3710.2 mmol/l and Sham:
84.378.3 U/l; Po0.001).
After the 2 weeks of reduced placental blood flow, the UPI
group had a significantly lower platelet count (UPI:
Table 1 | Relative vascularization of the placenta.
Pre-ligation angiogram Post-ligation angiogram
Cotyledons
supplied by LUA
Cotyledons
supplied by RUA
Cotyledons
supplied by LUA
Cotyledons
supplied by RUA
Uterine
artery ligated
UPI 1 12 8 (40%) 13 0 Right
UPI 2 6 (40%) 9 0 9 Left
UPI 3 15 10 (40%) 16 0 Right
LUA, left uterine artery; RUA, right uterine artery; UPI, uteroplacental ischemia.
The relative placental vascularization by left and right uterine arteries in the UPI group pre- and post-ligation.
The percentage ligated is calculated as percentage supplied by the artery of interest compared with the total arterial supply on the pre-ligation angiogram.
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271730 109/l and Sham: 304752 109/l; P¼ 0.031) and
higher hemoglobin (UPI: 12177.4 g/l and Sham: 11174.5 g/l;
Po0.001). There were no abnormalities detected in the
clotting studies or evidence of hemolysis.
Circulating sFLT-1
There was a significant increase in sFLT-1 in animals with
reduced placental blood flow (Figure 5). The baseline sFLT-1
concentration in the UPI group was 1489.47230 pg/ml and
increased to a peak of 13 223.372175 pg/ml at Day 3
(Po0.05). Over the similar time period, the Sham animals
plasma sFLT-1 concentration did not significantly change
(from 793.87423 pg/ml at baseline to 1939.67885.4 pg/ml
at Day 14; P40.05).
Placental sFLT-1 mRNA expression
Placental sFLT-1 mRNA expression was significantly greater in
the UPI group compared with the Sham group (Po0.001).
(Figure 6a). After 14 days of induced placental ischemia, sFLT-1
expression in the UPI group was significantly increased by
5492.574113% compared with a 15.9736% (Po0.05)
Sham group change in placental sFLT-1 mRNA expression.
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Figure 1 | Increase in Rest and Sleep SBP and DBP after UPI. The change in intra-arterial BP at rest and sleep compared with baseline was
monitored by implanted telemeters in pregnant baboons undergoing either selective unilateral uterine artery ligation (UPI, n¼ 3, circles) or
sham procedure (Sham, n¼ 2, squares). (a) Rest SBP change, (b) Rest DBP change, (c) Sleep SBP, (d) Sleep DBP. #Indicates a significant
difference between the UPI and Sham groups at the designated time point. *Indicates a significant difference between the marked data
point and baseline. mm Hg – millimeters of mercury, mean7s.e.m. displayed, significance set at Po0.05.
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Figure 2 | Urinary protein and albumin excretion increases after UPI. The excretion of urinary protein and albumin in pregnant baboons
that underwent UPI (UPI, n¼ 3, circles) and those that underwent a sham procedure (Sham, n¼ 2, squares). Clinically significant human
protein excretion is 30 mg/mmol (265 mg/g) (marked by dotted horizontal line). (a) Urinary protein excretion. (b) Urinary albumin excretion.
#Indicates a significant difference between the UPI and Sham groups at the designated time point. *Indicates a significant difference between
the marked data point and baseline. Mean7s.e.m. displayed, significance set at Po0.05. To convert from mg/mmol to mg/g, multiply
by 8.84.
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PBMC sFLT-1 mRNA expression
The animals undergoing a reduction in placental blood flow
expressed significantly greater PBMC sFLT-1 mRNA com-
pared with the Sham group (Po0.001) (Figure 6b).
Renal sFLT-1 mRNA expression
There was no significant difference between the UPI and
Sham groups in the renal expression of sFLT-1 mRNA
(P¼ 0.12) and no significant change in renal expression over
the course of the protocol (P¼ 0.86). The animals under-
going UPI had a 36.7719% and the Sham group a
44.0723% change in renal sFLT-1 mRNA expression
during the protocol.
DISCUSSION
UPI resulted in a clinical entity akin to human preeclampsia.
The animals undergoing UPI experienced an increase in BP,
the development of proteinuria as well as renal histological
changes and plasma biochemical changes noted in human
preeclampsia.
The study detailed a method by which UPI was established
in a non-human primate. A model was developed where the
extent of UPI was defined in a controlled manner. This is the
first study to successfully employ uterine angiography in a
pregnant baboon to delineate relative vascularization before
induction of UPI. Previous work has predominantly used
aortic constriction (with or without ovarian arterial clipping)
and has not visualized the extent of vascular supply to the
placenta at the time of proposed ischemia.15 The pre- and
post-ischemia angiography was critical to the success of this
project. It allowed for direct visualization and definition of
the arterial supply as well as defining the relative contribution
of the left and right uterine arteries to placental perfusion.
The post-procedure angiography allowed the confirmation of
the ligation of the correct structure.
The elevation in maternal BP in the baboons that
underwent UPI was substantial and significant. The change
in BP was chosen as the end point to minimize the effect of
small baseline variations and to reduce the numbers of
animals required. The SBP rise (of over 15 mm Hg) and DBP
rise (of over 15 mm Hg), as a result of the UPI, lead to a
a b
Figure 3 | Renal light microscopy changes identical to human
preeclampsia. Light microscopy changes in the baboon after 14
days of UPI were consistent with human renal changes in
preeclampsia (hematoxylin and eosin). Compared with the normal
baseline renal histology (a), after the induction of UPI renal biopsy
demonstrated (b) expansion of the mesangium (arrow), endothelial
cell swelling (arrow head), and reduction in capillary lumen were
noted.
a b
c d
Figure 4 | Renal electron microscopy changes identical to human
preeclampsia. Electron microscopy (a–d) demonstrated more
marked renal changes consistent with human preeclampsia than
light microscopy. Demonstrated is marked endotheliosis (a) with
some capillaries (cap) showing loss of endothelial cells and others
showing widening of the subendothelial space (white arrow), which
contains hyaline material (b). There was also evidence of mesangial
expansion (c, mes) and fibrin (f) and fibrinoid (fd) material within the
mesangium (d). It is important to note that in some areas the
podocyte foot processes (a and c, pp) are well preserved for the
degree of endotheliosis and proteinuria.
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Figure 5 | Plasma sFLT-1increases after the induction of UPI.
#Indicates a significant difference between the UPI (n¼ 3) and Sham
(n¼ 2) groups at the indicated time point. *Indicates a significant
difference between the marked data point and baseline.
Mean7s.e.m displayed, significance set at Po0.05.
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mean BP of 139/96 mm Hg. The UPI and Sham groups had
baseline BPs of 122/77 and 110/75 mm Hg, respectively.
These BPs are similar to the BPs seen at the corresponding
stage of pregnancy in other hemomonochorial placental
pregnancies, such as the human pregnancy. The elevation in
BP could only be attributed to the UPI as other confounding
variables (such as animal activity (reflecting pain) and
human interaction) were investigated and found to be no
different between the UPI and Sham groups. There was no
elevation in BP in the Sham group. The BP elevation in the
UPI group is similar in magnitude to the BP elevation noted
by Cavanagh et al.11 after sub-renal aortic constriction. They
found the BP to rise to 118/90 mm Hg. In this study, UPI was
undertaken in a more selective and measurable way. The
results of the study support the hypothesis that global
placental ischemia or hypoxia is a pathophysiological
mechanism resulting in hypertension in preeclampsia.
UPI also resulted in a significant elevation in the urinary
protein and albumin excretion. There was a statistically
significant difference in the protein and albumin excretion
between the two groups after 2 weeks of UPI. The degree of
protein and albumin excretion in the baboons undergoing
UPI was beyond the cutoff considered to be pathological in
humans. The definition of pathological proteinuria in human
pregnancy is considered to be a protein to creatinine ratio of
430 mg/mmol (265 mg/g).13 The UPI animals developed
‘clinically’ significant proteinuria between the Day 6 and Day
10 of UPI. The mirrored increase in albumin excretion
confirms that the majority of the protein excreted is albumin,
as is the case with human preeclampsia.14
Renal biopsy was also performed after the 2 weeks of UPI,
which demonstrated findings similar to those in women with
preeclampsia. These biopsies were crucial to this project.
They confirm that the unique renal histological changes
noted in human preeclampsia also occur in the baboons
undergoing UPI. The renal biopsies also prove definitively
that the proteinuria is not secondary to another renal
pathology, such as glomerulonephritis or acute hypertensive
nephrosclerosis. Other animal models that replicate the
hemodynamic changes of human preeclampsia do not
replicate the preeclampsia renal pathology or they demon-
strate other renal pathologies that result in hypertension and
proteinuria, such as glomerulonephritis.16
Similarly to women with preeclampsia,17 the UPI animals
demonstrated biochemically a reduction in renal function
and impaired placental function. Fetal growth, however, was
unaffected. The lack of fetal growth restriction may be
because the study was performed at near term and thus there
was not enough time to consider this a valid end point of the
study.
Hematological changes in the animals that underwent UPI
were reflected by a significantly lower platelet count and
higher hemoglobin. The diminished platelet count is
thought to represent the increased platelet turnover seen in
human preeclampsia,18 and the increased hemoglobin is
thought to represent the reduced plasma volume in human
preeclampsia.19
This project demonstrated a definite relationship between
placental ischemia and increased sFLT-1. UPI resulted in a
significant elevation in plasma sFLT-1. The elevation
occurred soon after the induction of ischemia, as it was
evident at Day 3 post-UPI. There was an approximately
10-fold rise in the plasma concentrations of sFLT-1. This is a
greater rise than that demonstrated in term pregnant women
with preeclampsia. Maynard et al.3 found that women with
severe preeclampsia had sFLT-1 concentrations approxi-
mately fivefold that of gestation matched normal controls.
Women with mild preeclampsia had sFLT-1 circulating levels
twice that of the controls. The rise in sFLT-1 in pregnant
women manifesting preeclampsia is gradual,5 reflecting the
insidious nature of the placental ischemia. The acute nature
of the induced experimental placental ischemia may explain
the greater elevation in sFLT-1 in the baboons. The more
chronic and progressive nature of the ischemia in women
might allow for the upregulation of vascular and hormonal
compensatory mechanisms.
The predominant source of the circulating sFLT-1 was the
placenta. The difference between the two groups became
statistically significant on Day 14 of UPI. This may reflect the
small number of animals in the study, but may also reflect
that the initial rise in sFLT-1 was due to the release of
preformed sFLT-1 rather than the increased production
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Figure 6 | Increase in placental and PBMC sFLT-1 mRNA expression after the induction of UPI. Using quantitative polymerase chain
reaction, sFLT-1 expression was assessed in serially obtained placental (a) and PBMC (b) samples. #Indicates a significant difference between the
UPI (n¼ 3) and Sham (n¼ 2) groups. Mean7s.e.m displayed, significance set at Po0.05.
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of sFLT-1. At Day 3, the UPC animals had a 1.3-fold greater
expression of sFLT-1 and by Day 14 they had a 1.8-fold
increase in sFLT-1 mRNA expression compared with the
Sham animals. Maynard et al.3 demonstrated that in women
with clinically established preeclampsia, the women with
severe preeclampsia had a five times elevation in mRNA
expression and women with mild preeclampsia had a 2.2-fold
increase in sFLT-1 mRNA. Others have demonstrated that the
sFLT-1 mRNA rise in women with preeclampsia is 1.6-fold
compared to controls.9 Both in human disease and in the
experimental preeclampsia, there is a disparity between the
elevation in serum sFLT-1 and the elevation in placental
sFLT-1 mRNA expression. This may in part be explained by
the contribution of other sources (such as PBMC) to the
circulating sFLT-1.9
This project also demonstrated that induction of ischemia
in the placenta may also affect sFLT-1 mRNA expression in
circulating cells not exposed directly to ischemia. The PBMC
elevation in sFLT-1 mRNA expression was 325% by Day 14 of
UPI compared with baseline. This is less than the 5290% rise
in placental sFLT-1 mRNA expression. There was a trend
towards an increase in PBMC sFLT-1 expression over the
duration of the protocol. This is in keeping with in vitro
findings. PBMC from pregnant women have been shown to
release a greater amount of sFLT-1 in vitro, however
Rajakumar et al.9 only measured culture medium sFLT-1
content and did not measure the sFLT-1 mRNA expression in
the cells. In view of the elevation in circulating sFLT-1 from
baseline during the protocol and the stability of the PBMC
expression, it may suggest that the contribution of the PBMC
may be by the release of preformed sFLT-1 or that there may
yet be another source. One other potential source is the
endothelium.
The endothelial bed accessible in this project was that of
the kidney. There was no increase in sFLT-1 mRNA expression
in the renal tissue as a result of the UPI. This may be because
the sFLT-1 mRNA was measured in the renal wedge biopsy as
a whole. The contribution of sFLT-1 mRNA of the endothelial
cells in the biopsy may have been masked by changes in other
cells in the kidney such as the tubules. Our results suggest the
kidney is a target organ of sFLT-1, rather than a source. Hara
et al.20 have demonstrated that elevated circulating sFLT-1
may result in proteinuria by downregulating nephrin, which
was not investigated in this study.
Recent work21 has demonstrated that soluble endoglin, a
transforming growth factor co-receptor is elevated in women
with preeclampsia. Together with sFLT-1, soluble endoglin
induced endothelial dysfunction in vivo and in vitro. Soluble
endoglin transcription has also been shown to be inducible
by hypoxia.22 Further work needs to be undertaken to study
the changes in soluble endoglin in this animal model of
preeclampsia utilizing UPI.
One limitation of this project was the small numbers of
animals used. However, post hoc power calculation revealed
that the study had 82% power with three animals in detecting
the 11 734 pg/ml difference in circulating sFLT-1 between
baseline and Day 3 post-UPI (given the standard deviation of
the difference was 3752 pg/ml).
The effects of UPI noted in this baboon model are
presumably applicable to humans, however, humans and
baboons differ. One of the most relevant differences is uric
acid metabolism. Baboons do not have circulating uric acid
under any condition as they endogenously produce uric acid
oxidase, a lytic agent for uric acid.23,24 Uric acid is an
important molecule in the diagnosis and assessment of
human preeclampsia.25 Uric acid has also been shown to be
independently able to injure directly the endothelium.26,27
Placental structure is also different between the species.
Grossly, implantation in the baboon compared with human,
is superficial and central with chorionic villi forming only
over the embryonic pole initially.28 This results in the
formation of the single discoid placenta with a membranous,
avillous paraplacental chorion and decidua capsularis.29
Microscopically, this reduced trophoblast invasion has been
characterized.30,31 Trophoblast invasion has only been
detected within decidual but not myometrial segments of
spiral arteries. Furthermore, interstitial trophoblast invasion
is limited and multinuclear giant cells not present.31
An invasive study such as this could not be performed in
pregnant women. Although other animal models are
available, the baboon is the most suited to these experiments.
Baboons predominantly have singleton pregnancies,32 with
an upright posture at rest and a hemochorial placenta.33 The
UPI mimicked the human syndrome of preeclampsia. It is
however an artificial phenomenon. The ischemia in the
project was created abruptly and the ovarian arteries were left
patent. In humans, it is most likely that the ischemia occurs
gradually. In the model employed by Cavanagh et al.,11 the
ischemia progressed slowly as the aorta and the ovarian
arteries were augmented before pregnancy. This study
examines the downstream events of placental ischemia (such
as the elevation in sFLT-1) and links them to changes in
blood flow. The cause of any postulated decrease in human
placental blood flow is not known.
In conclusion, placental ischemia results in significant
vascular dysfunction as is evidenced by the development of
hypertension and proteinuria. These effects are potentially
mediated by circulating sFLT-1, which in this study were
mainly derived from the placenta but also contributed to by
circulating mononuclear immunoregulatory cells.
MATERIALS AND METHODS
Protocol outline
Animals had UPI induced experimentally (UPI group) and the
results compared with animals undergoing a sham procedure (Sham
group). Radio-telemeters were implanted for BP measurement after
which the animals recuperated for 7 days. Baseline BP measure-
ments and samples (blood, urine, renal, and placental) were
obtained after the recuperation. Within 24 h of the baseline samples,
the UPI or Sham procedure was performed. During the ensuing 2
weeks blood, urine and placental samples were taken on Day 3, 7, 10,
and 14 after the UPI/Sham procedure. A progress renal biopsy was
also performed at the end of the protocol, Day 14 after UPI/Sham.
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Baboons
Female pregnant baboons (Papio hamadryas, n¼ 5) were from the
National Baboon Colony, New South Wales, Australia. Food and
water were provided ad libitum. At the beginning of the protocol,
the animals were 135 days pregnant of a normal 182 day gestation.
Animals were anesthetized using ketamine infusion (0.2 mg/kg/
min). This experiment was approved by the Royal Prince Alfred
(RPA) Animal Welfare Committee.
BP measurement
Radio-telemeters (PA-D70, DataSci, St Paul, MN, USA) were
surgically implanted to measure intra-arterial BP as described
previously.34 BP change expressed as the absolute change (mm Hg)
compared with baseline. Drift in BP measurement was measured
and adjusted for over the 2 weeks. BP at rest (Rest) BP was assessed
between 1600 and 2000 and BP during sleep (Sleep BP) between
2200 and 0300.
Induction of UPI
A percutaneous aortic angiogram was performed first. Vascular
access was gained via the femoral artery contra-lateral to the
telemeter insertion side. The arterial catheter (4F Soft-Vu
Omni-Flush, AngioDynamics) was inserted on to the aorta to the
level of the renal arteries and radio-opaque contrast (Ultravist,
Schering) injected. The catheter was subsequently inserted in to the
right or left uterine artery and a selective angiogram performed.
This allowed for visualization of the areas supplied by only one of
the uterine arteries. During angiography, each spiral vessel generated
a well-defined ‘blush’ of contrast, which corresponded to dye
entering the intervillous space of each cotyledon. The animal was
not moved during arterial ligation and the arterial introducer was
kept in place so a post-procedure angiogram could be performed. A
post-ligation angiogram was performed for confirmation of correct
vessel ligation and assessment of the degree of reduction in placental
perfusion.
Uterine artery ligation was undertaken through an ipsilateral
inguinal transperitoneal incision, whereas the angiogram introducer
was still in place. The iliac vessels were visualized and the uterine
artery identified at its point of origin from the internal iliac artery.
The uterine artery was dissected and irrigated with 1% lignocaine
solution to reduce arterial spasm. The vessel was then ligated with
4.0 silk sutures. The peritoneum, muscle, and skin were closed in
layers.
Animals underwent either a ligation of a unilateral uterine artery
(UPI group) or ligation of a small branch of the vesical artery
(Sham group). The uterine ligation was performed aiming to reduce
placental perfusion by approximately 30–50%. The total number
of placental blanches was counted on the aortic angiogram.
The selective uterine angiogram then permitted counting of the
portion of the placental blanches supplied by one of the uterine
arteries. The remaining blanches (those not supplied by the selected
uterine artery but evident on the aortic angiogram) were then
presumed to be supplied by the contralateral uterine artery. The
artery supplying o50% of the placental blanches was then selected
for ligation.
Specimen collection
Catheterized spot urinary protein excretion was adjusted for
creatinine excretion. Placental chorionic villous samples were
performed trans-abdominally as described previously.34 Plasma
and PBMC were collected and isolated as described previously.34
Enzyme-linked immunosorbent assay
Plasma sFLT-1 was measured by commercially available human
enzyme-linked immunosorbent assay (R&D, Minneapolis, MN,
USA). This enzyme-linked immunosorbent assay measures free
sFLT-1and has been described previously.3
Quantitative polymerase chain reaction
RNA was extracted from isolated PBMC, chorionic villous tissue and
renal tissue using a commercially available kit (NucleoSpin RNAII;
Macherey-Nagel), which has been described previously.35 One
microgram of RNA was reversed to cDNA using Superscript III
RNase Reverse Transcriptase (Invitrogen, Mount Waverly, Victoria,
Australia). Quantitative polymerase chain reaction was performed
by the comparative threshold cycle method and normalized to
b2-microglobulin expression. The primers used for sFLT-1 and
b2-microglobulin have been described.
8,35 RNA expression is
expressed as the percentage change compared with baseline samples.
Statistical analysis
Statistical analysis was performed (using SPSSTMv11.0) with two-way
analysis of variance and post hoc Tukey’s test where applicable after
logarithmic transformation. Data expressed as mean7s.e.m.
Significance set at Po0.05.
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